Answers are grounded in this paper and cite their sources.
Peroxisome proliferator-activated receptor γ (PPARγ) agonists, also known as thiazolidinediones (TZDs), are used as insulin-sensitizing agents to treat type 2 diabetes. Examples include pioglitazone (Actos®), rosiglitazone (Avandia®), and others such as troglitazone, farglitazar (GI262570), and GW7845. Side effects of TZD therapy include fluid retention and peripheral edema. The weight gain from fluid retention is undesirable from a cosmetic standpoint but more seriously can adversely affect comorbidity in the diabetic state.1 Reported effects of PPARγ agonists on cardiovascular function are mixed. One recent high-profile study found that rosiglitazone increases the risk of death from cardiovascular disease,2 although other studies observe beneficial effects of pioglitazone on major cardiovascular events in humans3 and protection against ischemia–reperfusion injury and reduction of myocardial infarct size in animal models.4 Regardless of the risk–benefit relationships of PPARγ agonist therapy, it is clear that fluid retention exacerbates compromised cardiac function and lessens patient compliance with drug treatment. Unfortunately, PPARγ-agonist-induced fluid retention is refractory to most first-line diuretic therapies.5 The nature of PPARγ-agonist-induced fluid retention suggests an integrated physiologic response that includes a primary effect on renal regulation of salt and water balance. PPARγ is expressed in the collecting duct, suggesting that ligands for this receptor modulate salt and water homeostasis through ion transport systems in this nephron segment. The epithelial Na+ channel (ENaC) expressed in collecting duct principal cells is regulated by steroid (aldosterone) and peptide hormones (insulin, IGF-1, and vasopressin) and represents a key control point for the modulation of salt reabsorption and, consequently, BP. It is logical, therefore, to postulate that ENaC is a likely target of a PPARγ agonist effect. Unfortunately, studies performed to substantiate this relationship are contradictory, and it is difficult to establish a consensus as to potential mechanisms. Two different collecting-duct-specific PPARγ null mouse models showed …
No takes yet. Share an insight, caveat, or question.
Nofziger et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: